What is Gryphus Diagnostics?
Established in 1998 in Birmingham, AL, Gryphus Diagnostics has carved a niche in the medical device industry through its innovative development and manufacture of rapid detection systems. The company achieved its first FDA release in May 2000, paving the way for a portfolio of products currently undergoing investigation. Gryphus holds a U.S. patent for its sialidase technology platform, issued in early 2003. Its products, registered and approved in numerous countries, are distributed globally to point-of-care facilities, hospitals, and clinical laboratories. With a strong emphasis on quality, Gryphus operates under stringent ISO 9001:2000, ISO 13485:1996, and CMDCAS registrations, adhering to FDA guidelines within its cGMP manufacturing facility. The company's commitment to advancing women's health through its product pipeline and R&D efforts is a key differentiator.
How much funding has Gryphus Diagnostics raised?
Gryphus Diagnostics has raised a total of $84K across 1 funding round:
Debt
$84K
Debt (2021): $84K with participation from PPP
Key Investors in Gryphus Diagnostics
PPP
Public-Private Partnership
What's next for Gryphus Diagnostics?
The substantial expansion capital secured by Gryphus Diagnostics at this significant Series B/C stage indicates a strategic move towards scaling operations and potentially broadening its market reach. This financing is likely to fuel further research and development, enhance manufacturing capabilities, and support the global commercialization of its advanced rapid detection systems, particularly in the women's health sector. The company's focus on quality and regulatory compliance suggests a continued emphasis on market penetration and establishing a robust presence in key international markets.
See full Gryphus Diagnostics company page
